Stocks To Buy Now

Blog


OurPet’s Company (OPCO) Reroutes Communication Plan to Maximize Outreach, Better Utilize Funds

OurPet’s Company designs, produces and markets a broad line of innovative pet products and accessories under the OurPets and Pet Zone brands, sold in leading pet specialty retailers, food, drug and mass merchandisers, direct-mail catalog and Internet retailers. The company’s extensive product line is built on its intellectual property portfolio of more than 160 patents in either issued or pending status.

Coinciding with corporate growth among its target markets, OurPet’s yesterday announced a new strategy to more efficiently utilize corporate resources. Moving forward, OurPet’s says it will no longer conduct quarterly earnings teleconferences, and instead is ramping up its online communications and social media strategies to ensure that shareholders have ongoing access to the company’s most recent news, financial reports and progress.

“We have hosted consistent quarterly earnings calls for the 18 months, and have not seen participation meet our targets. In light of this, we feel that we can allocate our funds toward more worthy causes, and have identified more far-reaching and cost-effect routes to disseminate company news and financial reports,” OurPet’s CFO Scott Mendes stated in the news release. “This decision further emphasizes our commitment to increasing shareholder value, transparency and communication. We look forward to providing our shareholders and potential investors with more readily available, up-to-date corporate information.”

As part of its new communications strategy, OurPet’s recently engaged DreamTeamNetwork to boost its social media, presence, disseminate news releases, achieve targeted marketing and establish a mobile version of the OurPet’s website.

For more information visit www.ourpets.com and www.petzonebrand.com

Let us hear your thoughts: OurPet’s Co. Message Board

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.